A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides

Experimental Nephrology

Volumn 5, Issue 5, 1997, Pages 429-434

  Tomita, Naruya ^a   Morishita, Ryuichi ^a   Higaki, Jitsuo ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

BASE SEQUENCE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; TRANSCRIPTION FACTORS;

EID: 0030707859     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Sullenger BA, Gallardo HF, Unger GE, Giboa E: Overexpression of TAR sequence renders cells resistant in human immunodificiency virus replication. Cell 1990;63:601-608.
2. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ: Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990;250:996-1000.
3. Latchhman DS: Transcription factor mutations and disease. N Engl J Med 1996;334:28-33.
4. Dzau VJ, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996;93:11421-11425.
5. Hiebert SW, Lipp M, Nevins JR: E1A-dependent trans-activation of the human myc promoter is mediated by the E2F factor. Proc Natl Acad Sci USA 1989;86:3594-3598.
6. Morishita R, Gibbons GH, Horiuchi M, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A novel molecular strategy using cis element decoy of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.
7. Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y, Ogihara T: Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992;186:129-134.
8. Tomita N, Kim J, Gibbons GH, Baran D, Ogborn M, Stahl RAK, Tomita S, Zhang L, Kaneda Y, Dzau VJ: In vivo gene therapy of anti-Thy 1 nephritis using E2F decoy oligonucleotide (abstract). J Am Soc Nephrol 1995;6: 887.
9. Baeuerle PA, Henkel T: Function and activation of NFκB in the immune system. Annu Rev Immunol 1994;12:141-179.
10. Tamura K, Umehara S, Ishii M, Takimoto K, Murakami K, Fukamizu A: Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. J Clin Invest 1994;93:1370-1379.
11. Morishita R, Higaki J, Tomita N, Aoki M, Moriguchi A, Tamura K, Murakami K, Kaneda Y, Ogihara T: Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Hypertension 1996;27:502-507.
12. Yamada T, Horiuchi M, Morishita R, Zhang L, Pratt RE, Dzau VJ: In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. J Clin Invest 1995;96:1230-1237.